Souhaitez-vous accéder aux communiqués récents ?

Oslo, January 31, 2025: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its fourth quarter 2024 results...

Oslo, January 27, 2025: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, invites to a webcast presentation of its...

Oslo, 9 January 2025: Reference is made to the stock exchange notices published by Ultimovacs ASA (the "Company") on (i) 17 December 2024 regarding the contemplated business combination between the...

Oslo, January 9, 2025: Ultimovacs ASA held its extraordinary general meeting today January 9, 2025. All the matters on the agenda were approved. The minutes from the meeting are enclosed and...

Oslo, January 8, 2025: In connection with the Extraordinary General Meeting of Ultimovacs ASA to be held on January 9, 2025, Jónas Einarsson, Chair of the Board of Directors, has so far received...

Oslo, January 6, 2025: In connection with the Extraordinary General Meeting of Ultimovacs ASA to be held on January 9, 2025, Jónas Einarsson, Chair of the Board of Directors, has so far received...

  Oslo, 5 January 2025: Reference is made to the stock exchange notice published by Ultimovacs ASA on 19 December 2024 regarding the call for an extraordinary general meeting to be held on 9 January...

  Oslo, 19 December 2024: Reference is made to the stock exchange notice published by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the contemplated business combination between the...

Oslo, 19 December 2024: Reference is made to the stock exchange notice published by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the contemplated business combination between the...

Issuer name: Ultimovacs ASA Ex. date: 18 December 2024 Type of corporate action: Potential repair offering  Other information: Any repair offering is subject to the prior publication of a...